Prevention and treatment of space sickness in Shuttle-Orbiter missions

A status report is presented on assessments of antimotion sickness drugs in slow-rotation rooms and, particularly, with two candidate medications - fixed-dose combinations of promethazine plus ephedrine and a transdermal therapeutic system-scopalamine - that are efficacious over long periods with acceptable side effects. Attention is given to evaluating the use of free fall in parabolic flight as a model for orbital flight to assess the efficacy of antimotion sickness drugs. Experience in slow-rotation rooms suggests that programming adaptation (executing head movements) is significantly superior to random head movements when performing required tasks.